Loading
Life sciences · Journal article
Cancers · September 17, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Pediatric malignancies are often closely linked to developmental cell states, differentiation trajectories, and restricted developmental windows. This relationship is especially evident in neural-crest-derived tumors, where malignant cells may retain, remodel, or reacquire glycosylation programs that normally regulate embryonic migration and lineage maturation. Using a pediatric developmental perspective, we consider tumor-associated sialylation as potentially reflecting retention of the developmental cell-of-origin glycome, reacquisition during malignant cell state plasticity, or cancer-specific remodeling. Neuroblastoma provides the strongest evidence linking these mechanisms to tumor biology and therapy. Polysialylated NCAM can support migratory and plastic phenotypes, ganglioside biosynthesis is coupled to adrenergic-mesenchymal cell state through cell state-dependent regulation of glycosyltransferases including ST8SIA1, and the developmentally enriched ganglioside GD2 creates an actionable therapeutic vulnerability. Selected neural-crest-derived tumors that also occur outside childhood are included as they may help distinguish lineage-associated mechanisms from features specific to pediatric malignancy. We examine sialoglycan-Siglec immune regulation, emerging glycan-directed therapies, and approaches for resolving sialylation across developmental and malignant cell states. This framework argues that pediatric neural-crest-derived tumors do not simply recapitulate embryonic glycosylation but selectively retain, remodel, or reacquire developmental sialylation programs that can influence plasticity, migration, immune evasion, and therapeutic response.